| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V36584-1mg |
≥99% | ￥196.00 |
货期：3-5天 | - | - | - | - |
|
V36584-5mg |
≥99% | ￥450.00 |
货期：3-5天 | - | - | - | - |
|
V36584-10mg |
≥99% | ￥630.00 |
货期：3-5天 | - | - | - | - |
|
V36584-25mg |
≥99% | ￥1150.00 |
货期：3-5天 | - | - | - | - |
|
V36584-50mg |
≥99% | ￥1680.00 |
货期：3-5天 | - | - | - | - |
|
V36584-100mg |
≥99% | ￥2470.00 |
货期：3-5天 | - | - | - | - |
|
| 靶点： | IC50: 0.13 nM (c-MET) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体内研究： | Capmatinib (INCB28060) (1-30 mg/kg; PO, twice daily, for 2 weeks) exhibits dose-dependent inhibition of tumor growth, and shows well tolerance at all doses during the treatment periods, with no evidence of overt toxicity or weight loss in U-87MG tumor mice model. Capmatinib (INCB28060) (0.03-10 mg/kg; PO, single dosage) causes inhibition of c-MET phosphorylation in S114 tumor mice model. |
||||||||||||||||||||
| 参考文献： | 1. Liu X, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. Clin Cancer Res. 2011 Nov 15;17(22):7127-38. 2. Baltschukat S, et al. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation. Clin Cancer Res. 2019 May 15;25(10):3164-3175. 3. Dhillon S. Capmatinib: First Approval. Drugs. 2020 Jul;80(11):1125-1131. |
||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京